2-[(2S)-2-amino-3,3-dimethylbutyl]isoindole-1,3-dione | 848777-79-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: 2-[(2S)-2-amino-3,3-dimethylbutyl]isoindole-1,3-dione
• CAS: 848777-79-7
• 化学式: C₁₄H₁₈N₂O₂
• 分子量: 246.309
• InChiKey: VBVMPKMNTTUJLZ-LLVKDONJSA-N

物化性质

• 沸点：
  367.5±25.0 °C(Predicted)
• 密度：
  1.171±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  63.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-[(2S)-2-amino-3,3-dimethylbutyl]isoindole-1,3-dione 在 一水合肼 、 三乙胺 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 2.0h， 生成
  参考文献：
  名称：

  Asymmetric Multicomponent Sulfa-Michael/Mannich Cascade Reaction: Synthetic Access to 1,2-Diamino-3-Organosulfur Compounds and 2-Nitro Allylic Amines

  摘要：

  A novel catalytic asymmetric three-component intermolecular sulfa-Michael/Mannich cascade reaction has been developed using a chiral multifunctional catalyst. This reaction provides facile access to 1-amino-2-nitro-3-organosulfur compounds bearing three consecutive stereocenters in high yields (up to 96%) with good diastereo- (up to 91:4:4:1 dr) and excellent enantioselectivities (93-99% ee). Furthermore, the products of this reaction could be facilely transformed into potentially bioactive 1, 2-diamino-3-organosulfur compounds and 2-nitro allylic amines.

  DOI：

  10.1021/acs.orglett.5b02423
• 作为产物：
  描述：

  L-叔亮氨醇 在 偶氮二甲酸二异丙酯 、 三苯基膦 、 三氟乙酸 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成 2-[(2S)-2-amino-3,3-dimethylbutyl]isoindole-1,3-dione
  参考文献：
  名称：

  Asymmetric Multicomponent Sulfa-Michael/Mannich Cascade Reaction: Synthetic Access to 1,2-Diamino-3-Organosulfur Compounds and 2-Nitro Allylic Amines

  摘要：

  A novel catalytic asymmetric three-component intermolecular sulfa-Michael/Mannich cascade reaction has been developed using a chiral multifunctional catalyst. This reaction provides facile access to 1-amino-2-nitro-3-organosulfur compounds bearing three consecutive stereocenters in high yields (up to 96%) with good diastereo- (up to 91:4:4:1 dr) and excellent enantioselectivities (93-99% ee). Furthermore, the products of this reaction could be facilely transformed into potentially bioactive 1, 2-diamino-3-organosulfur compounds and 2-nitro allylic amines.

  DOI：

  10.1021/acs.orglett.5b02423

文献信息

• [EN] NOVEL KETOAMIDES WITH CYCLIC P4'S AS INHIBITORS OF NS3 SERINE PROTEASE OF HEPATITIS C VIRUS<br/>[FR] NOUVEAUX CETOAMIDES A P4 CYCLIQUES EN TANT QU'INHIBITEURS DE LA NS3 SERINE PROTEASE DU VIRUS DE L'HEPATITE C
  申请人：SCHERING CORP

  公开号：WO2005085242A1

  公开（公告）日：2005-09-15

  The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.

  本发明公开了具有HCV蛋白酶抑制活性的新化合物，以及制备这种化合物的方法。在另一实施方式中，该发明公开了包含这种化合物的药物组合物，以及使用它们治疗与HCV蛋白酶相关的疾病的方法。
• [EN] MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE<br/>[FR] INHIBITEURS MACROCYCLIQUES DE LA SERINE PROTEASE NS3 DU VIRUS DE L'HEPATITE C
  申请人：SCHERING CORP

  公开号：WO2005030796A1

  公开（公告）日：2005-04-07

  The present invention discloses novel compounds which have HCV protease inhibitory activity as well as pharmaceutical compositions comprising such compounds and methods of using them to treat disorders associated with the HCV protease. The novel compounds typically include a 15-20 member macrocycle and have the general structure of structural Formula (1): wherein Z', L', M', R1, X and D are defined herein.

  本发明揭示了一种新型化合物，其具有HCV蛋白酶抑制活性，以及包含这些化合物的制药组合物和使用它们治疗与HCV蛋白酶相关的疾病的方法。这些新型化合物通常包括一个15-20成员的大环，并具有以下结构式（1）的一般结构，其中Z'、L'、M'、R1、X和D在此被定义。
• SUBSTITUTED IMIDAZOHETEROCYCLES
  申请人：Beckett R. Paul

  公开号：US20090149450A1

  公开（公告）日：2009-06-11

  The present invention provides substituted imidazoheterocyclic compounds having the structure of formula I Also provided are pharmaceutically acceptable salts, acid salts, hydrates, solvates and stereoisomers of the compounds of formula I. The compounds are useful as modulators of cannabinoid receptors and for the prophylaxis and treatment of cannabinoid receptor-associated diseases and conditions, such as pain, inflammation and pruritis.

  本发明提供了具有公式I结构的取代咪唑杂环化合物，同时还提供了公式I化合物的药学上可接受的盐、酸盐、水合物、溶剂合物和立体异构体。该化合物可用作大麻素受体调节剂，并用于预防和治疗与大麻素受体相关的疾病和症状，例如疼痛、炎症和瘙痒等。
• NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF
  申请人：FUJIFILM Corporation

  公开号：EP2589592A1

  公开（公告）日：2013-05-08

  An object of the present invention is to provide to a compound and a pharmaceutical composition, which have excellent Syk-inhibitory activity. Th e present invention provides a nicotinamide derivative represented by the follo wing formula (I) (wherein R1 represents a halogen atom; R2 represents a C1-12 alkyl group, a C2-12 alkenyl group, a C2-12 alkynyl group, a C3-8 cycloalkyl g roup, an aryl group, an ar-C1-6 alkyl group or a heterocyclic group, each opti onally having at least one substituent; R3 represents an aryl group or a hetero cyclic group each optionally having at least one substituent; and R4 and R5 e ach independently represent a hydrogen atom; and R2 and R4 may form a cyc lic amino group optionally having at least one substituent together with the ni trogen atom to which they bind) or a salt thereof, and a pharmaceutical comp osition for use in the treatment of a Syk-related disease which comprises the nicotinamide derivative or a salt thereof.

  本发明的目的是提供一种化合物和药物组合物，其具有优异的抑制 Syk 的活性。本发明提供了一种烟酰胺衍生物，由以下式（I）表示 其中 R1 代表卤素原子；R2 代表 C1-12 烷基、C2-12 烯基、C2-12 炔基、C3-8 环烷基、芳基、ar-C1-6 烷基或杂环基，每个基团可选择具有至少一个取代基；R3 代表芳基或杂环基，每个基团可选择具有至少一个取代基；以及 R4 和 R5 分别独立地代表一个氢原子；R2 和 R4 可与它们结合的氮原子一起形成一个环状氨基，该氨基可选择具有至少一个取代基）或其盐，以及一种用于治疗 Syk 相关疾病的药物组合物，该药物组合物包含烟酰胺衍生物或其盐。
• Second-Generation Highly Potent and Selective Inhibitors of the Hepatitis C Virus NS3 Serine Protease
  作者：Kevin X. Chen、Latha Nair、Bancha Vibulbhan、Weiying Yang、Ashok Arasappan、Stephane L. Bogen、Srikanth Venkatraman、Frank Bennett、Weidong Pan、Melissa L. Blackman、Angela I. Padilla、Andrew Prongay、Kuo-Chi Cheng、Xiao Tong、Neng-Yang Shih、F. George Njoroge

  DOI：10.1021/jm801238q

  日期：2009.3.12

  The hepatitis C virus (HCV) infection is a leading cause of chronic liver disease. The moderate efficacy along with side effects of the current pegylated interferon and ribavirin combination therapy underscores the need for more effective and safer new treatment. In an effort to improve upon our current clinical candidate, Boceprevir (SCH 503034), extensive SAR studies were performed on the P3 capping moieties. This led to the discovery of tert-leucinol derived cyclic imides as a potent series of novel P3 capping groups. Thus, the introduction of these imide caps improved the cell-based replicon EC90 by more than 10-fold. A number of imides with various substitutions, ring sizes, bicyclic systems, and heterocyclic rings were explored. The 4,4-dimethyl substituted glutarimide emerged as the best cap as exemplified in compound 21 (K-i* = 4 nM, EC90 = 40 nM). Systematic optimization of different positions (P', P3, and P1) of the inhibitor resulted in the identification of the lead compound 46, which had an excellent potency (K-i* = 4 nM, EC90 = 30 nM) and good pharmacokinetic profile (22% and 35% bioavailability in rats and dogs, respectively). X-ray structure of inhibitor 46 bound to the enzyme revealed that there was an additional hydrogen bonding interaction between one of the imide carbonyls and Cys159.